强迫性阻塞性心肌病的治疗选择:以患者为中心的综述
Chiara Cirillo1, Andrea Perillo1, Emanuele Monda1
1Inherited and Rare Cardiovascular Disease Unit, Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', AORN dei Colli, Monaldi Hospital, Naples, Italy.
Expert review of cardiovascular therapy
|December 5, 2024
概括
本综述涵盖了超性心肌病 (HCM) 的当前和新兴疗法,强调个性化治疗计划. 它强调了根据个体患者的需求和偏好量身定制护理的重要性,以获得管理HCM的最佳结果.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 增高性心肌病变 (HCM) 是一种遗传性心脏病,其特征是左心室壁厚度增加.
- 患病率估计在1:200-500,具有显著的家族组成部分.
- 医疗和手术治疗的进步改善了HCM的预后.
研究的目的:
- 审查当前的药理学和非药理学治疗方法,以治疗多变性心肌病 (HCM).
- 探索新的治疗方法和个性化患者护理在HCM管理中的重要性.
- 讨论未来的前景,包括新的药物和基因治疗HCM.
主要方法:
- 对现有关于HCM治疗的数据进行批判性评估.
- 对β-阻断剂,通道阻断剂,迪索皮拉米德和心脏肌抑制剂的证据的讨论.
- 对预防突然死亡的策略和隔膜缩小疗法 (手术和非手术) 的审查.
主要成果:
- 证据支持目前用于HCM症状管理的药理干预措施.
- 对HCM突发心脏病死亡预防的数据和争议的分析.
- 探索新兴疗法,包括新药和基因治疗HCM.
结论:
- 一个个性化的,以患者为中心的方法对于最佳的缩性心肌病 (HCM) 管理至关重要.
- 治疗策略应该整合表型,风险分层和个体患者的偏好.
- 正在进行的新疗法研究有望进一步改善HCM患者的治疗结果.
相关概念视频
Myocarditis III: Medical Management
1
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
1
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Mitral Regurgitation III: Medical Management
4
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
4
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Mitral Valve Prolapse II: Assessment and Management
2
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
2


